Ionis Pharmaceuticals (NASDAQ:IONS) reported Q2 2025 GAAP revenue and non-GAAP earnings per share that exceeded analyst expectations by wide margins. The profit surge in Q2 2025 included a ...

WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver ...

Revenue declined sharply to $8.7 million in Q2 fiscal year 2025, missing analyst expectations by 34.1% and falling 55.8% compared to the prior year period. Net loss widened to $50.5 million for Q2 ...

Nucleic acid therapies offer targeted treatment for genetic diseases, but delivery remains a key hurdle. Explore how advances ...

Delivers Second-Quarter Net Revenues of $15.423 Billion, an Increase of 6.6 Percent on a Reported Basis or 6.5 Percent on an Operational Basis "AbbVie delivered another outstanding quarter with strong ...

A WEHI-led study reveals that blocking minor splicing – an RNA process critical for cell division – reduces tumour growth in ...

Researchers have found in ALPACA trial that Lepodisiran demonstrated a substantial reduction in lipoprotein(a) levels, ...

In a statement, the Cambridge, Massachusetts-based company said that shipments of Elevidys (delandistrogene moxeparvovec) will restart while it continues dialogue with the FDA "on next steps in the ...

Regulators block Duchenne muscular dystrophy treatment after fatal side-effects outweigh questionable efficacy ...

The remainder of 2025 will be busy for Vir Biotechnology as it strives to successfully pivot to developing cancer and infectious disease therapies.

Different levels of two neuropeptides can turn leafcutter ants into soldiers, farmers, or nurses, highlighting their role in ...

UMass President Marty Meehan and healthcare leaders emphasize UMass Chan’s future success depends on its next chancellor’s ability to cultivate talent, face federal challenges head-on, invest in ...